Shares of Zydus Lifesciences were trading in the green and 1% higher on 18 October after the company received approval from the US Food and Drug Administration (USFDA) to manufacture Fludrocortisone Acetate Tablets USP, 0.1 mg. 

The Fludrocortisone Acetate Tablets USP, 0.1 mg, are used as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison’s disease and for the treatment of salt-losing adrenogenital syndrome.

The tablets will be manufactured at the company’s manufacturing site at Moriya, Ahmedabad. 

Since the starting of the company’s filing process in fiscal year 2003-04, Zydus Lifesciences has received 400 approvals and has filed over 465 abbreviated new drug applications (ANDAs). 

Earlier on 10 October, the company received tentative approval from the USFDA to manufacture Enzalutamide Tablets, 40 mg and 80 mg.

On 2 October, the company received final approval to manufacture Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg from the USFDA. 

The company has also signed a Memorandum of Agreement (MoA) with the Indian Council of Medical Research to begin Phase 2 clinical trials of Desidustat in patients with Sickle Cell Disease.

At 12:30 pm, the shares of Zydus Lifesciences were trading 0.26% higher at Rs 1,023.55 on NSE.

Feeling overwhelmed by the markets? Let Unicorn Signals be your guide. Our user-friendly app simplifies complex data and provides actionable trading signals. Download the app today and trade with confidence!